CSF3 and myocardial infarction: Of note, the first clinical trial [SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI)] investigating the effect of a combination of sitagliptin and G-CSF in nondiabetic patients with acute MI has been conducted [40].